Skip to main content
    C

    Charles River Laboratories (CRL)

    Official site

    HEALTHCARE • DIAGNOSTICS & RESEARCH • NYSE

    $332.11
    -3.41 (-1.02%)

    Market Cap: $16.08B

    Last updated: Nov 17, 2026 at 4:20 PM ET

    Charles River Laboratories (CRL) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    Charles River Laboratories (CRL) has a market cap of $16.08B and an enterprise value of $18.32B. Its return on invested capital of 0.06% compares with a 8.18% median across 10 similar companies. Its trailing P/E of 31.4x is above its 10-year median of 20.5x.

    Total Valuation

    Enterprise value is 13.95% above the market cap, as debt exceeds cash.

    Market Cap$16.08B
    Enterprise Value$18.32B
    Latest price (Nov 17, 2026)$332.11

    Key Dates

    The next earnings report is expected on Feb 16, 2027, covering the quarter ending Dec 31, 2026.

    Next Earnings DateFeb 16, 2027 (expected)
    Last Earnings DateNov 4, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count fell 0.45% in the quarter ended Sep 30, 2026 and shrank 3.56% a year over 2 years.

    Shares Outstanding47.80M
    Shares Change (YoY)-2.87%
    Shares Change (QoQ)-0.45%
    Share Count Growth (2Y CAGR)-3.56%

    Valuation Ratios

    Sales and book value multiples are 4.0x and 4.9x. Its year-end P/E ranged from 16.7x to 36.5x from 2016 to 2025.

    P/E Ratio31.4x
    Forward P/E28.7x
    P/S Ratio4.0x
    Forward P/S4.1x
    P/B Ratio4.9x
    P/FCF Ratio39.7x
    P/OCF Ratio25.8x
    PEG Ratio3.2

    Valuation history and multiples

    Enterprise Valuation

    Counting debt and cash, the company is valued at 62.5x EBITDA and 45.3x free cash flow.

    EV / Earnings430.1x
    EV / Sales4.6x
    EV / EBITDA62.5x
    EV / FCF45.3x

    Price Statistics

    The stock is up 97.91% over 52 weeks and trades 6.10% above its 50-day average.

    Beta (1Y)1.26
    52-Week Change+97.91%
    1-Month Change+10.70%
    3-Month Change+14.52%
    6-Month Change+117.88%
    5-Year Change-19.90%
    10-Year Change+373.66%
    Total Return (1Y)+97.91%
    Total Return (3Y CAGR)+20.66%
    Total Return (5Y CAGR)-3.04%
    Return vs SPY (1Y)+92.78%
    Max Drawdown (1Y)-33.88%
    Max Drawdown (3Y)-63.52%
    Sharpe Ratio (1Y)1.52
    Correlation with SPY (1Y)0.37
    50-Day Average$313.03
    200-Day Average$228.93
    52-Week Range$146.20 to $379.63
    RSI (14 Days)50.0
    Average Volume (20 Days)1.28M

    The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 1.41x current liabilities, and total debt is 0.76x shareholder equity.

    Current Ratio1.41x
    Quick Ratio1.12x
    Debt / Equity0.76x
    Debt / EBITDA8.42x
    Debt / FCF6.11x
    Interest Coverage0.05x

    Returns and Efficiency

    Return on invested capital is 0.06% over the last 12 months, against a 5-year average of 0.05%.

    Return on Equity (ROE)1.32%
    Return on Assets (ROA)0.57%
    Return on Invested Capital (ROIC)0.06%
    Return on Capital Employed (ROCE)0.08%
    ROE (5Y Average)8.38%
    ROA (5Y Average)3.27%
    ROIC (5Y Average)0.05%
    Asset Turnover0.53x
    Inventory Turnover7.96x
    Receivables Turnover5.50x
    Cash Conversion Cycle93 days

    Scores

    CRL has an Altman Z-Score of 3.21, in the safe zone above 2.99, and a Piotroski F-Score of 5 of 9, in the average band of 3 to 7.

    Altman Z-Score3.21
    Altman Z ZoneSafe
    Piotroski F-Score5 of 9
    Piotroski StrengthAverage

    Income Statement

    Revenue of $3.98B over the last 12 months is down 1.16% from the 12 months before.

    Revenue$3.98B
    Revenue Growth (YoY)-1.16%
    Gross Profit$1.33B
    Operating Income$158.98M
    Pretax Income-$100.21M
    Net Income$42.59M
    EBITDA$290.11M
    EBIT$5.13M
    Reported EPS (TTM)$10.56

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Shareholder equity funds 43.36% of the $7.45B in total assets.

    Cash and Equivalents$200.38M
    Total Debt$2.44B
    Net Debt$2.24B
    Net Debt Per Share$46.92
    Working Capital$445.77M
    Shareholder Equity$3.23B
    Book Value Per Share$67.51
    Tangible Book Value-$95.76M
    Total Assets$7.45B
    Total Liabilities$4.18B

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    After $222.77M of capital spending, operating cash flow left $399.63M of free cash flow.

    Operating Cash Flow$622.41M
    Capital Expenditures$222.77M
    Free Cash Flow$399.63M
    FCF Per Share$8.37
    Depreciation and Amortization$284.98M
    Share Repurchases$324.20M

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Margins

    The operating margin is 4.00%, against a 5-year average of 10.84%.

    Gross Margin33.33%
    Operating Margin4.00%
    Pretax Margin-2.52%
    Net Margin1.07%
    EBITDA Margin7.29%
    EBIT Margin0.13%
    FCF Margin10.05%
    Gross Margin (5Y Average)35.34%
    Operating Margin (5Y Average)10.84%
    Net Margin (5Y Average)6.47%

    Growth

    Revenue grew 0.33% a year over 3 years, and EPS fell 2.61% a year.

    Revenue Growth (3Y CAGR)+0.33%
    Revenue Growth (5Y CAGR)+6.55%
    EPS Growth (3Y CAGR)-2.61%
    EPS Growth (5Y CAGR)+4.78%
    FCF Growth (3Y CAGR)+20.69%
    FCF Growth (5Y CAGR)+6.41%
    Operating Income Growth (3Y CAGR)-66.19%
    Book Value Per Share Growth (2Y CAGR)-3.93%

    Revenue and profit by year

    Dividends and Yields

    CRL does not pay a dividend. Its free cash flow yield is 2.52%.

    Earnings Yield3.18%
    FCF Yield2.52%
    Buyback Yield2.04%
    Shareholder Yield2.04%

    Peer Position

    Against 10 similar companies, CRL has the 5th highest P/E and the 10th highest ROIC.

    P/E Ratio31.4x vs 24.9x median
    P/S Ratio4.0x vs 5.2x median
    ROIC0.06% vs 8.18% median
    Revenue Growth (Trailing 4 Quarters, YoY)-1.16% vs +8.99% median

    Competitors compared

    Analyst Forecast

    Consensus estimates put revenue growth at 0.57% and EPS growth at 12.32% a year over the next 2 fiscal years.

    Revenue Growth Forecast (2Y CAGR)+0.57%
    EPS Growth Forecast (2Y CAGR)+12.32%

    Analyst estimates by year

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    GNG Valuation

    GNG viewOvervalued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About CRL

    What is CRL's market cap?

    Charles River Laboratories has a market cap of $16.08B. Its enterprise value, which adds debt and subtracts cash, is $18.32B.

    What is CRL's P/E ratio?

    Charles River Laboratories has a trailing P/E ratio of 31.4x and a forward P/E of 28.7x.

    How many shares of CRL are outstanding?

    Charles River Laboratories has 47.80M shares outstanding. The count is down 2.87% from a year earlier.

    Does CRL pay a dividend?

    No. Charles River Laboratories does not pay a dividend.

    How much debt does CRL have?

    Charles River Laboratories has $2.44B of total debt and $200.38M of cash and equivalents, a net debt position of $2.24B.